Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
5.59
+0.12 (2.19%)
At close: Oct 23, 2026, 4:00 PM EDT
5.32
-0.27 (-4.86%)
After-hours: Oct 23, 2026, 7:44 PM EDT
Orchestra BioMed Holdings Revenue
Orchestra BioMed Holdings had revenue of $88.00K in the quarter ending June 30, 2026, a decrease of -89.47%. This brings the company's total for the last twelve months to $31.98M, up 986.14% year-over-year. In the year 2025, Orchestra BioMed Holdings had annual revenue of $33.48M with 1,169.22% growth. That makes Orchestra BioMed Holdings the 30,944th largest company in the world by revenue and 4,080th in the United States.
Revenue (ttm)
$31.98M
Revenue Growth
+986.14%
P/S Ratio
10.51
Revenue / Employee
$371,814
Employees
86
Market Cap
335.99M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 33.48M | 30.84M | 1,169.22% |
| Dec 31, 2024 | 2.64M | -122.00K | -4.42% |
| Dec 31, 2023 | 2.76M | -773.00K | -21.88% |
| Dec 31, 2022 | 3.53M | 4.32M | - |
| Dec 31, 2021 | -782.00K | -6.49M | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Enanta Pharmaceuticals | 65.26M |
| Fennec Pharmaceuticals | 59.22M |
| vTv Therapeutics | 36.84M |
| X4 Pharmaceuticals | 15.85M |
| Capricor Therapeutics | 11.13M |
| YD Bio | 1.24M |
OBIO News
- 1 day ago - Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB - GlobeNewsWire
- 22 days ago - Orchestra BioMed surpasses full enrollment in BACKBEAT trial - TheFly
- 22 days ago - Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy - GlobeNewsWire
- 24 days ago - OBIO's Capital Access Advisory Program (CAAP®) Reaches Milestone with $1 Billion Raised by High-Growth Life Sciences and Health Tech Ventures - Business Wire
- 5 weeks ago - Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026 - GlobeNewsWire
- 5 weeks ago - Orchestra BioMed receives $6.1M milestone payment from Haemonetics - TheFly
- 5 weeks ago - Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics - GlobeNewsWire
- 5 weeks ago - Orchestra BioMed price target raised to $11 from $10 at B. Riley - TheFly